Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents

New clinical trials for diabetic macular oedema (DMO) are being designed to prove superiority over aflibercept when this agent is already very effective in improving visual acuity (VA) and DMO. The aim of this study was to determine the optimal inclusion–exclusion criteria for trials to aim for supe...

Descripción completa

Detalles Bibliográficos
Autores principales: Halim, Sandra, Gurudas, Sarega, Chandra, Shruti, Greenwood, John, Sivaprasad, Sobha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536417/
https://www.ncbi.nlm.nih.gov/pubmed/33020570
http://dx.doi.org/10.1038/s41598-020-73571-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536417/
https://www.ncbi.nlm.nih.gov/pubmed/33020570
http://dx.doi.org/10.1038/s41598-020-73571-6

Ejemplares similares